Market Eyes LiveResMed Inc. (RMD) Stock Rating & Analysis
MELANY's data-driven read on ResMed Inc. · Surgical & Medical Instruments & Apparatus.
ResMed is among the largest respiratory care device companies worldwide, primarily developing and supplying flow generators, masks, and accessories to treat sleep apnea. Rising sleep apnea diagnosis, aging populations, and increasing obesity prevalence are driving structural market growth. The company earns roughly two-thirds of its revenue in the Americas, with the remainder spread across other regions led by Europe, Japan, and Australia.
Why RMD scores 60/100
MELANY scores ResMed Inc. 60/100 by weighing eight factors. Here is how RMD breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 61%
- ROE 24%
Direction and relative strength of the recent share-price trend.
- Price +12.0% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
What Wall Street price targets and revisions are signalling.
- Institutional net buying +31.2%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for RMD
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
ResMed Inc. sits in the Healthcare sector theme, which MELANY currently rates 50/100 for strength. Theme strength feeds RMD's momentum and catalyst factors above.
Tracking RMD
ResMed Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add RMD to your watchlist and get alerted the moment the rating changes.
How MELANY rates RMD
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. ResMed Inc.'s 60/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about RMD
Is ResMed Inc. (RMD) a buy?
As of 2026-08-24, MELANY rated ResMed Inc. Hold with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is ResMed Inc.'s MELANY score?
ResMed Inc. (RMD) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the RMD stock rating calculated?
MELANY scores RMD from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy ResMed Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates ResMed Inc. (RMD) Hold with a composite of 60/100 as of 2026-08-24. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the RMD stock price forecast?
MELANY does not publish price targets or forecasts for RMD. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for ResMed Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is RMD stock overvalued or undervalued?
MELANY's valuation factor currently reads 54/100 for ResMed Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives RMD's read.
What price should I buy RMD at?
MELANY is not flagging a fresh entry for RMD at its current Hold rating, so there is no entry zone to publish right now. Watchlisting RMD in the free app gets you alerted the moment that changes.
What are the risks of buying RMD stock?
The top risks MELANY currently flags for ResMed Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is ResMed Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 84/100 for ResMed Inc., and earnings track record, at 65/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will RMD stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 50/100 for RMD right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this RMD rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-24. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores RMD continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
RMD's live rating and alerts are free either way. The app is our flagship.